233 related articles for article (PubMed ID: 31705612)
21. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
Diamantova D; Lomickova I; Cetkovska P
Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
[TBL] [Abstract][Full Text] [Related]
23. Uncommon pretibial bilateral manifestation of Hidradenitis suppurativa (Hurley III) after discontinuation of systemic treatment with adalimumab: a serious reason to prefer surgery as a primary approach?
Tchernev G; Temelkova I; Wollina U
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e449-e451. PubMed ID: 31273867
[No Abstract] [Full Text] [Related]
24. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
[TBL] [Abstract][Full Text] [Related]
25. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
26. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
Samycia M; Brassard A
J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
[TBL] [Abstract][Full Text] [Related]
27. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of co-existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexate.
Genovese G; Caorsi R; Moltrasio C; Marzano AV
J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():40-41. PubMed ID: 31535768
[TBL] [Abstract][Full Text] [Related]
29. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
[TBL] [Abstract][Full Text] [Related]
30. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
[TBL] [Abstract][Full Text] [Related]
31. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
32. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
[TBL] [Abstract][Full Text] [Related]
33. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
34. Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab.
Atzori L; Zanniello R; Pilloni L; Rongioletti F
J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():42-44. PubMed ID: 31535759
[TBL] [Abstract][Full Text] [Related]
35. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
Tchernev G
Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
[TBL] [Abstract][Full Text] [Related]
36. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
39. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
Zouboulis CC
Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]